NAD+ depletion links metabolic stress to drive innate immune priming and selectively control PANoptosis

R Roman Sarkar (Department of Immunology, St. Jude Children’s Research Hospital) N Nagakannan Pandian (St. Jude Children’s Research Hospital) B Balamurugan Sundaram (Department of Immunology, St. Jude Children’s Research Hospital) B Bhesh Raj Sharma (Department of Immunology, St. Jude Children’s Research Hospital , Memphis, TN,) P Peter A Gorsuch (Department of Immunology, St. Jude Children’s Research Hospital , Memphis, TN,) R Rebecca E Tweedell (Department of Immunology, St. Jude Children’s Research Hospital , Memphis, TN,) T Thirumala-Devi Kanneganti (Department of Immunology, St. Jude Children’s Research Hospital)

Abstract

Abstract The innate immune system can detect infection, tissue damage, and other homeostatic disruptions to initiate an immune response, drive inflammation, and promote programmed cell death. While these responses can be beneficial in host defense, aberrant activation of inflammatory, lytic cell death pathways can be pathogenic. Emerging evidence suggests that cellular metabolic disruption can promote inflammatory cell death, but the mechanistic connections between these processes are not well understood, limiting our ability to identify regulatory nodes that can be therapeutically targeted. Here, we found that intracellular levels of the metabolic cofactor nicotinamide adenine dinucleotide (NAD+) were depleted in response to cell death triggers that drive pyroptosis, necroptosis, PANoptosis, and ferroptosis. However, restoring NAD+ inhibited PANoptosis but not the other forms of cell death. Mechanistically, NAD+ restoration reduced the expression of PANoptotic sensors or regulators, including the transcription factor IRF1, a critical factor for innate immune sensor priming in PANoptosis. Our findings thereby suggest that NAD+ depletion is an early cell death signaling event and that restoring NAD+ levels specifically blocks PANoptosis by suppressing priming. Hence, targeting NAD+ metabolism represents a potential therapeutic strategy for infectious and inflammatory diseases associated with dysregulated PANoptosis.

Article Details

Volume / Issue Vol. 215, Issue 7
Published July 10, 2026
ISSN 0022-1767
Publisher American Association of Immunologists

Authors (7)

R

Roman Sarkar

Department of Immunology, St. Jude Children’s Research Hospital

N

Nagakannan Pandian

St. Jude Children’s Research Hospital

B

Balamurugan Sundaram

Department of Immunology, St. Jude Children’s Research Hospital

B

Bhesh Raj Sharma

Department of Immunology, St. Jude Children’s Research Hospital , Memphis, TN,

P

Peter A Gorsuch

Department of Immunology, St. Jude Children’s Research Hospital , Memphis, TN,

R

Rebecca E Tweedell

Department of Immunology, St. Jude Children’s Research Hospital , Memphis, TN,

T

Thirumala-Devi Kanneganti

Department of Immunology, St. Jude Children’s Research Hospital